It approves tissue-based NGS companion diagnostic for Takeda's targeted therapy for NSCLC patients with EGFR Exon20 insertion mutations
The deal is expected to close in the fourth quarter of 2021 and will enable Roche to further expand the portfolio. TIB Molbiol excels in ultra-rapid assay development of emerging infectious diseases
These were the findings of the Post Marketing Surveillance (PMS), study of Favipiravir (FabiFlu) on over 1000 patients
The first lot of IPV will be supplied to the government this month as per the requirement of the Health Ministry
_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
Laurus will be incentivised for a portion of its development and commercialisation costs. CHAI will also provide technical and regulatory support to enable accelerated generic development
The net proceeds from the issue will be utilised towards the purchase of machinery, modernising existing units and expansion of its R&D facilities
Research collaboration covers multiple antibody research programs
The institute will provide the world’s first unique and comprehensive capability to predict, prevent, respond and to recover from future pandemics
One batch has 11.4 million units of Naproxen tablets out of which 0.9 million units that were released into the market were recalled
Subscribe To Our Newsletter & Stay Updated
